3ZO0 Stock Chart & Stats
€5.09
--
Market closed
€5.09
--
Day’s Range― - ―
52-Week Range€5.09 - €10.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€6.01M
Enterprise Value-€6.81M
Total Cash (Recent Filing)€9.25M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.14
Next Earnings
Aug 17, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.86Price Target Upside192.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase II EfficacyRobust Phase II results demonstrating high cure and no early recurrences provide durable clinical validation of ibezapolstat's mechanism. This strengthens the drug's evidentiary base for registrational strategy, supports competitive positioning versus existing therapies, and reduces scientific development risk going into larger trials.
Regulatory Pathway ClarityThe formalized single‑trial pathway and LPAD option materially lower structural regulatory hurdles for CDI programs. This can shorten development timelines, reduce the scale and cost of pivotal work, and meaningfully de‑risk approval strategy versus historic multi‑trial expectations for antibacterial approvals.
Strengthened Patent PortfolioA multi-jurisdictional patent estate with patents extending toward 2039 provides a durable commercial exclusivity window. This strengthens bargaining leverage for licensing or partnerships, supports potential future pricing power, and creates a substantive barrier to generic/competitive entry over the crucial post-approval commercialization period.
Bears Say
Pre-revenue With Cash BurnThe company remains pre‑revenue and consistently cash‑flow negative, meaning operations are not self‑funding. Sustainable progress depends on external capital, which creates ongoing dilution and execution risk; absent product sales, financial flexibility and long‑term planning remain constrained.
Modest Cash Vs Phase III NeedsA ~$9.3M cash balance is small relative to anticipated Phase III and registration costs, implying near‑term funding needs. This structural funding gap risks program delays, truncated trial designs, or dilutive financings to sustain pivotal development and regulatory interactions over the next 2–6 months and beyond.
Small RCDI Pilot SizeA 20‑patient open‑label pilot yields limited statistical robustness and external validity; regulators will likely require larger randomized active‑controlled trials for definitive evidence. This structural limitation increases the probability of extended development timelines and higher incremental trial costs to achieve approval‑grade data.
Acurx Pharmaceuticals News
3ZO0 FAQ
What was Acurx Pharmaceuticals Llc’s price range in the past 12 months?
Acurx Pharmaceuticals Llc lowest stock price was €5.09 and its highest was €10.36 in the past 12 months.
What is Acurx Pharmaceuticals Llc’s market cap?
Acurx Pharmaceuticals Llc’s market cap is €6.01M.
When is Acurx Pharmaceuticals Llc’s upcoming earnings report date?
Acurx Pharmaceuticals Llc’s upcoming earnings report date is Aug 17, 2026 which is in 43 days.
How were Acurx Pharmaceuticals Llc’s earnings last quarter?
Acurx Pharmaceuticals Llc released its earnings results on May 12, 2026. The company reported -€0.534 earnings per share for the quarter, beating the consensus estimate of -€1.033 by €0.499.
Is Acurx Pharmaceuticals Llc overvalued?
According to Wall Street analysts Acurx Pharmaceuticals Llc’s price is currently Undervalued.
Does Acurx Pharmaceuticals Llc pay dividends?
Acurx Pharmaceuticals Llc does not currently pay dividends.
What is Acurx Pharmaceuticals Llc’s EPS estimate?
Acurx Pharmaceuticals Llc’s EPS estimate is -0.32.
How many shares outstanding does Acurx Pharmaceuticals Llc have?
Acurx Pharmaceuticals Llc has 4,297,738 shares outstanding.
What happened to Acurx Pharmaceuticals Llc’s price movement after its last earnings report?
Acurx Pharmaceuticals Llc reported an EPS of -€0.534 in its last earnings report, beating expectations of -€1.033. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals Llc?
Currently, no hedge funds are holding shares in DE:3ZO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals Llc
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
3ZO0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.View all DE:3ZO0 earnings summaries3ZO0 Stock 12 Month Forecast
Average Price Target
€14.86
▲(192.01% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―
Options Prices
Currently, No data available
---